Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
Status:
Completed
Trial end date:
2015-01-31
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve
SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects
with Genotype(GT)-1b, -4 and GT-2, -3